Alcon price target lowered to $87 from $95 at Baird

Baird analyst Jeff Johnson lowered the firm’s price target on Alcon to $87 from $95 and keeps an Outperform rating on the shares. The firm said ophthalmic surgical end market demand seems to be normalizing a bit faster than expected, which takes a bit off the firm’s organic growth outlook for this part of the company’s business moving forward.